Roche (RHHBY) Downgraded by Societe Generale

Roche (OTCMKTS:RHHBY) was downgraded by Societe Generale from a “hold” rating to a “sell” rating in a research report issued to clients and investors on Monday, The Fly reports.

A number of other equities analysts have also commented on the stock. Zacks Investment Research lowered shares of Roche from a “buy” rating to a “hold” rating in a research report on Friday, January 5th. JPMorgan Chase & Co. reaffirmed an “overweight” rating on shares of Roche in a research report on Friday, December 29th. Piper Jaffray Companies reaffirmed a “buy” rating on shares of Roche in a research report on Thursday, December 7th. Berenberg Bank lowered shares of Roche from a “buy” rating to a “hold” rating in a research report on Tuesday, October 24th. Finally, Citigroup lowered shares of Roche from a “buy” rating to a “neutral” rating in a research report on Wednesday, October 18th. Three investment analysts have rated the stock with a sell rating, seven have issued a hold rating and five have issued a buy rating to the stock. The company currently has an average rating of “Hold” and a consensus price target of $36.50.

Shares of Roche (RHHBY) opened at $31.78 on Monday. Roche has a 1 year low of $28.48 and a 1 year high of $36.82. The company has a debt-to-equity ratio of 0.66, a current ratio of 1.29 and a quick ratio of 0.92.

Several hedge funds and other institutional investors have recently added to or reduced their stakes in RHHBY. Parametric Portfolio Associates LLC boosted its stake in shares of Roche by 5.6% during the third quarter. Parametric Portfolio Associates LLC now owns 3,806,074 shares of the company’s stock valued at $121,794,000 after purchasing an additional 200,394 shares in the last quarter. Lenox Wealth Management Inc. boosted its stake in Roche by 49.0% in the third quarter. Lenox Wealth Management Inc. now owns 98,282 shares of the company’s stock valued at $3,145,000 after acquiring an additional 32,335 shares in the last quarter. Chickasaw Capital Management LLC boosted its stake in Roche by 33.3% in the fourth quarter. Chickasaw Capital Management LLC now owns 40,000 shares of the company’s stock valued at $1,265,000 after acquiring an additional 10,000 shares in the last quarter. Stonebridge Capital Advisors LLC acquired a new stake in Roche in the third quarter valued at approximately $221,000. Finally, Patten Group Inc. boosted its stake in Roche by 12.2% in the third quarter. Patten Group Inc. now owns 29,741 shares of the company’s stock valued at $847,000 after acquiring an additional 3,239 shares in the last quarter. Hedge funds and other institutional investors own 0.58% of the company’s stock.

TRADEMARK VIOLATION WARNING: This article was posted by American Banking News and is the sole property of of American Banking News. If you are accessing this article on another domain, it was copied illegally and reposted in violation of U.S. & international copyright and trademark legislation. The legal version of this article can be viewed at https://www.americanbankingnews.com/2018/01/15/roche-rhhby-downgraded-by-societe-generale.html.

Roche Company Profile

Roche Holding AG (Roche) is a research-based healthcare company. The Company’s operating businesses are organized into two divisions: Pharmaceuticals and Diagnostics. The Pharmaceuticals Division consists of two business segments: Roche Pharmaceuticals and Chugai. The Diagnostics Division consists of four business areas: Diabetes Care, Molecular Diagnostics, Professional Diagnostics and Tissue Diagnostics.

The Fly

Analyst Recommendations for Roche (OTCMKTS:RHHBY)

Receive News & Ratings for Roche Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Roche and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply